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Abstract
Introduction—We previously reported a unique hypothalamic-pituitary-thyroid (HPT) axis
profile in women with a menstrually related mood disorder (MRMD) who also had a history of
sexual abuse (SA). In the present study, we sought to extend that work by examining the
association of a SA history with HPT-axis disturbance in both MRMD and non-MRMD women.
Methods—Fifty-seven women met prospective criteria for MRMD (23 with a SA history) and 52
women were non-MRMD (18 with a SA history). Thyroid stimulating hormone (TSH), T4, (total
and free) and T3 (total and free) were evaluated in serum together with thyroid hormone ratios
reflecting T4 to T3 conversion.
Results—MRMD women, compared with non-MRMD women, had elevated T3/T4 ratios
(ps≤0.01; reflecting increased conversion of T4 to T3) and lower free and total T4 concentrations
(ps=0.01). Higher T3/T4 ratios and lower T4 concentrations predicted more severe premenstrual
symptomatology in all women. A SA history, irrespective of MRMD status, was associated with
elevated TSH concentrations (p=0.03). However, in MRMD women, a SA history was associated
with elevated T3 concentrations (p=0.049), whereas in non-MRMD women, a SA history was
associated with decreased T3 concentrations (p=0.02).
Conclusions—A MRMD and a SA history are associated with independent as well as
interactive effects on the HPT-axis. The evidence that a MRMD moderates the influence of SA on
T3 concentrations contributes to a growing body of work suggesting that a SA history may
identify a distinct subgroup of women with MRMD.
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Introduction
Alterations in the hypothalamus-pituitary-thyroid (HPT) axis are well described in mood
disorders, particularly in stress related disorders (1–3). Briefly, activation of the HPT-axis
involves hypothalamic release of thyrotropin-releasing hormone (TRH) that stimulates the
pituitary release of thyroid stimulating hormone (TSH) that in turn activates the thyroidal
production and release of the thyroid hormones, including thyroxin (T4) and tri-
iodothyronine (T3), the more biologically potent thyroid hormone. The primary secretory
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product of the thyroid gland is T4, whereas the majority of T3 comes from extra-thyroidal
conversion from T4 via deiodination (1,2).
While the HPT-axis is not responsive to minor stress, it is responsive to severe traumatic
stress (4). A number of studies in men with combat related post-traumatic stress disorder
(PTSD) have documented elevated T3 concentrations, together with an increase in the T3/T4
ratio, an index of increased peripheral conversion of T4 to T3 (5–7). The clinical relevance
of this HPT-axis pattern in combat-related PTSD is suggested by the correlation of elevated
T3 concentrations with more severe PTSD symptoms (6,8).
Sexual abuse (SA) represents another traumatic event with estimated lifetime prevalence of
up to 22% in the general female population (9). Friedman and colleagues (2005) showed that
women with PTSD due to childhood SA had similar HPT-axis profiles as men with combat-
related PTSD with evidence for increased peripheral T4 to T3 conversion together with
elevated T3 concentrations. Again, there was a positive correlation of PTSD symptoms with
T3 concentrations and with the T3/T4 ratio (10).
In addition to PTSD, it has been consistently shown that SA histories are more prevalent in
menstrually related mood disorders (MRMDs) (11–13). Up to 30% of childbearing age
women experience some form a MRMD, and reported prevalence rates of the more severe
form of a MRMD, premenstrual dysphoric disorder, range from 1.3% (after controlling for
co-morbid psychopathology) (14) to 7% (15,16). MRMDs are characterized by significant
emotional symptoms, physical symptoms and functional impairment that are isolated to the
luteal phase of the menstrual cycle (17). Early research on the HPT-axis function in MRMD
was inconclusive (18–21). However, more recent research suggests that a SA history may
identify a subgroup of MRMD women for whom the HPT-axis is clinically relevant.
Work from our group has shown that MRMD women with a SA history exhibit higher
serum T3 concentrations, a greater T3/T4 ratio, and TSH concentrations 75% greater when
compared with both non-abused MRMD women and non-abused non-MRMD controls, a
pattern remarkably similar to that reported in combat and SA related PTSD (22). These
results suggested that MRMD women with a SA history have enhanced central drive of the
HPT-axis and increased peripheral T4 to T3 conversion. Additionally, in MRMD women,
we found that greater T3 concentrations were associated with more severe premenstrual
symptoms (22) similar to findings in PTSD (6,8,10). However, our interpretation of those
results was limited by the absence of a group of non-MRMD women with a SA history.
Consequently, in a larger sample than previously studied, we sought to evaluate whether the
HPT-axis profile that we previously observed in MRMD women with SA histories (22) is
unique to MRMD women with SA, and therefore may be of pathophysiological relevance,
or would be evident in all women with SA histories. The conceptual framework guiding this
investigation is based on the ample evidence that either very severe traumatic events or
traumatic events experienced during critical developmental periods set lifetime trajectories
for abnormalities in neuroendocrine systems, which can consequently contribute to poor
mental and somatic health outcomes (23–25). Moreover, because MRMD women show
unique long-term cardiovascular and adrenergic sequalea associated with an abuse history
that is not seen in non-MRMD women with similar histories (13,26), we hypothesized that a
history of SA would be associated with greater TSH and T3 concentrations and a greater T4
to T3 conversion in MRMD women only. We also sought to evaluate the clinical relevance
of any HPT-axis dysregulation by examining the relationship of HPT-axis measures and
premenstrual symptoms. We hypothesized that increased T4 to T3 conversion indices would
be associated with more severe premenstrual symptoms.
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The study protocol was approved by the University of North Carolina at Chapel Hill
Committee on the Protection of the Rights of Human Subjects.
Women were recruited via newspaper, radio or posted advertisements targeting women with
severe premenstrual symptoms (MRMD women) or women without premenstrual symptoms
(non-MRMD women). In order to obtain roughly equal proportions of women with a history
of SA in the two diagnostic groups it was necessary to selectively recruit non-MRMD
women with abuse histories. After confirming MRMD status (below), women were invited
for a diagnostic visit, during which they were assessed by a trained interviewer for medical
histories, for current and past Axis I psychiatric disorders according to the Diagnostic and
Statistical Manual of Mental Disorders 4th edition-Text revision (DSM-IV-TR) (27) using
the MINI structured psychiatric interview (28) and for abuse histories using a validated
structured interview (29). Also, during the same visit blood samples were drawn for
evaluation of HPT-axis hormones concentrations. Women were included in the study if they
were in good health, without current chronic medical conditions, including thyroid
disorders, or current DSM-IV Axis I psychiatric disorders, including PTSD. None of the
subjects was taking prescription medication including oral contraceptives, thyroid
medications or psychotropic medications.
A total of 109 women were in our final sample: (a) MRMD with SA histories (n=23; 21%),
(b) MRMD without SA histories (n=34; 31%), (c) non-MRMD with SA histories (n=18;
17%) and (d) non-MRMD without SA histories (n=34; 31%). Although the prevalence of
SA histories in the subgroup of non-MRMD women was higher than the general population
(9) due to targeted recruitment of non-MRMD women with an abuse history, the
proportional distribution of women with a SA in the MRMD and non-MRMD groups was
still not absolutely equivalent due to the well-documented association between MRMD and
abuse histories (11–13).
MRMD diagnosis
MRMD and non-MRMD status was confirmed prospectively using the Daily record of
severity of problems (DRSP) (30) that all women completed daily for two to three menstrual
cycles. Forms were mailed back weekly in order to discourage retrospective reporting. The
DRSP consists of 21 items and allows for the quantification of the severity of physical,
emotional and behavioral symptoms of MRMD using a 6-point scale (1 absent, 2 minimal, 3
mild, 4 moderate, 5 severe and 6 extreme). To classify participants as having MRMD, each
met the following criteria: (1) at least a 30% change in emotional symptom severity between
the seven luteal phase days preceding menses compared with follicular phase days 4–10; (2)
a rating of emotional symptoms as moderate, severe or extreme on at least two of the seven
premenstrual days; (3) remission of symptoms shortly after the onset of menses followed by
a clear symptom free period (≥ 6 consecutive days) during the early-to-mid follicular phase
and (4) criteria 1–3 met in at least two menstrual cycles (30,31). Non-MRMD women met
the following criteria: (1) no more than minimal emotional symptoms occurring on fewer
than three days during the premenstrual week; (2) less than a 30% change in emotional
symptom severity from the luteal to the follicular phase; and (3) these criteria met in at least
two menstrual cycles.
Assessment of SA histories
A history of SA was verified using a validated structured interview (29), and included the
following experiences in which force or threat of harm was used: (a) sexual touching with
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hands, mouth, or objects; (b) making the subject touch the perpetrator with hands, mouth, or
objects; and (c) making the subject have vaginal or anal intercourse. If the subject was
younger than 13 years of age at the time of first episode of SA, force or threat of harm was
not required if implied by the age differential between perpetrator and victim. This measure
of SA history has been associated with multiple measures of poor mental and physical health
status in several studies (29,32). In addition, with this instrument, SA history is ascertained
by interview using behaviorally specific questions after rapport with patients has been
established. This type of methodology has been associated with more reliable and valid
responses compared with other abuse history assessments (23).
Assessment of psychiatric histories
The MINI structured diagnostic interview (28) was used to evaluate all women for current
and past psychiatric disorders. All diagnoses were based on a consensus diagnostic session
with a clinical psychologist. Since lifetime histories of depressive disorders are prevalent in
women with MRMD (33), one year in full remission was required for depressive disorders,
while for other Axis I disorders three years in remission was required. However, two women
who technically met criteria for current anxiety disorders were allowed to participate in the
study. One of these women had current Agoraphobia, but her fear of crowds was not
associated with Panic attacks. The other woman met criteria for MRMD and for generalized
anxiety disorder but her anxiety was restricted in nature and was exacerbated during the
premenstrual phase suggesting that her anxiety symptoms were a feature of her MRMD.
Hypothalamic-pituitary-thyroid axis Variables and Assays
Serum concentrations of TSH, total T4, free T4, total T3, free T3, and thyroid binding
globulin (TBG) were evaluated. The majority of circulating thyroid hormones are bound to
TBG and only a small fraction is unbound (or free) and biologically active. Hence, serum
concentrations of T3 and T4 are measured as both free, which includes only unbound
hormone, and total, which includes both bound and free hormone, fractions. Thyroid
hormones ratios that reflect peripheral conversion of T4 to T3 and thyroid hormones binding
were also calculated. The free T3/free T4ratio and total T3/free T4 ratio reflect peripheral
conversion of T4 to T3, with higher ratios indicating more conversion. The free T3/total T3
ratio and free T4/total T4 ratio reflect thyroid hormone binding to serum proteins, with
lower ratios indicating more binding.
Blood samples for the evaluation of HPT-axis hormones were drawn at a single time-point
between 7:00 AM and 9:30 AM (median time of 9:00 AM) without respect to menstrual
cycle phase. All women were required to have had at least 6 hours of sleep the night before
the venipuncture. Blood was collected into serum separator tubes. Blood samples were
centrifuged and serum was frozen at −40 °C. The samples from all patients for each
parameter were analyzed in a single batch. Concentrations of thyroid hormones were
measured by radioimmunoassay procedures using commercial kitspurchased from Becton-
Dickinson. The intra-assay and inter-assay coefficients of variation were, respectively, 6%
and 8% for total T4, 5% and 8% for free T4, 5% and 7% for total T3, 4%and 7% for free T3,
and 7% and 9% for TBG.
Data analysis
First, we compared the four subgroups of women with respect to demographic
characteristics (age and ethnicity), sexual abuse histories (age at first SA and years since last
SA), psychiatric histories (depressive disorders, anxiety disorders, PTSD and substance and/
or alcohol abuse and/or dependence) and premenstrual symptom severity. A 2 (SA history)
× 2 (MRMD status) analysis of variance was used to compare continuous data and Pearson’s
Chi-squared test was used to compare categorical data. Significant interactions were
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followed by post-hoc analyses using the Scheffe test for continuous data and Pearson’s Chi-
squared test or Fisher’s exact t-test, as appropriate, for categorical data.
Second, we examined individual and interactive effects of current MRMD status and SA
histories on concentrations and ratios of thyroid hormones. For each of the six thyroid
hormones and four ratios we performed univariate general linear model analyses with each
thyroid measure as the dependent variable and with MRMD status (MRMD or non-MRMD)
and SA history (SA history or no SA history) as between-subjects factors. Where significant
interactions emerged, they were followed with post-hoc analyses using the independent-
samples t-test.
Finally, using Spearman’s rank order correlation, we evaluated the association between
premenstrual symptom severity and HPT-axis measures. Average premenstrual symptom
severity from the first menstrual cycle was analyzed in order to avoid the confound that
repeated symptom monitoring over several months may have on symptoms (34). Core
MRMD premenstrual symptoms included: depression (“felt depressed, sad, “down” or
“blue”, “felt hopeless” and “felt worthless or guilty”), anxiety symptom (“felt anxious,
“keyed up” or “on edge””), mood lability (“had mood swings” and “was more sensitive to
rejection or my feelings were easily hurt”) and anger (“felt angry, irritable” and “had
conflicts or problems with people”). Luteal phase symptoms were averaged over the six
days preceding menses.
Data were analyzed with the PASW 18.0 for Windows (Chicago, Illinois). All continuous
data are expressed as means ± standard deviations, all categorical data as number and
percent.
Results
Demographics and Psychiatric Histories
There were no differences between the four subgroups in age, ethnicity, age at first SA
experience, time since last SA experience, or prevalence of past anxiety disorders (Table 1).
Histories of depressive disorders, PTSD and substance and/or alcohol abuse or dependence
were more prevalent in non-MRMD women with SA histories relative to non-MRMD
women with no SA history (X2 = 14.44, p < 0.001, Fisher’s exact test p < 0.001 and p =
0.005, respectively). Histories of alcohol and/or substance abuse or dependence were also
more prevalent in MRMD women with SA histories relative to MRMD women with no SA
histories (X2 = 13.07, p < 0.001). As expected, total premenstrual symptom severity and
each of the core symptom severities was higher in MRDM women when compared to non-
MRMD women irrespective of SA histories (ps < 0.001; data not shown).
HPT-Axis Measures
Table 2 summarizes results of HPT-axis measures stratified by MRMD status and by SA
histories. All women with a SA history, irrespective of MRMD status, had higher TSH
concentrations (F [108, 3] = 4.88; p = 0.03; Figure 1) and a lower free T3/total T3 ratio (F
[108, 3] = 3.92; p = 0.05), the latter suggesting increased binding of T3 in women with SA
histories.
On the other hand, MRMD women, irrespective of abuse histories, had lower free T4 (F
[108, 3] = 8.28; p = 0.01) and total T4 concentrations (F [108, 3] = 6.30; p = 0.01), and
higher free T3/free T4 ratio (F [108, 3] = 18.39; p < 0.001) and total T3/free T4 ratios (F
[108, 3] = 7.82; p = 0.01; Figure 2), relative to non-MRMD women. This HPT-axis pattern
suggests an increase in peripheral conversion of T4 to T3 in MRMD women.
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There was an MRMD x SA interaction for free T3 concentrations (F [108, 3] = 5.42;
p=0.02; Table 2) and a trend for total T3 concentrations (F [108, 3] = 3.77; p = 0.055),
reflecting the directionally different effect that a SA history had on T3 concentrations in
MRMD versus non-MRMD women. Post-hoc analyses revealed that MRMD women with
SA histories had elevated free T3 concentrations compared with non-MRMD women with
SA histories (t = −2.03, p = 0.049), while non-MRMD women with SA histories had lower
free T3 concentrations than non-MRMD women without SA histories (t = −2.53, p = 0.02).
Although same pattern was evident for total T3 concentrations, individual paired
comparisons were not statistically significant.
Relationship of thyroid hormones and luteal phase symptoms
Because many women have some premenstrual symptomatology, albeit not MRMD, and
because we have previously documented that a history of abuse is associated with greater
premenstrual symptom severity in both MRMD and non-MRMD women (29), we examined
the relationship of HPT-axis measures to premenstrual symptoms in the full sample of
women. Lower free and total T4 concentrations, and higher free T3/free T4 and total T3/free
T4 ratios (all ps <0.05; Table 3) were associated with greater premenstrual anxiety, mood
lability and anger symptom severity and total symptom severity. A higher free T3/free T4
ratio was also correlated with greater premenstrual depressive symptom severity (p<0.001).
Discussion
The results of this study suggest that MRMD status and SA histories are associated with
independent, as well as interactive effects on the HPT-axis. For example, greater free T3/
free T4 and total T3/free T4 ratios together with lower T4 serum concentrations in MRMD
women when compared to non-MRMD women suggest increased peripheral conversion of
T4 to T3 in MRMD. Whether the increased peripheral T4 to T3 conversion also reflects
greater central conversion in MRMD we cannot say. However, peripheral thyroid hormones
readily cross into brain via energy-dependent transport mechanisms (1,2). Thus, it would be
unusual for central events to go unchanged when the brain receives a distinctly different
proportion of T3 to T4. Furthermore, we found that the low T4 concentrations and elevated
T3/T4 ratios were associated with increased premenstrual symptom severity in the entire
sample. Additional clinical relevance of increased T4 to T3 conversion that we found in
MRMD women (22) and that Wang with colleagues have reported in PTSD (6,8) comes
from the evidence that propranolol, a centrally acting beta-adrenergic receptor blocker, is
widely used in treatment of thyrotoxicosis and is effective in reducing T3 concentrations
(35). Animal studies have shown that propranolol decreases the expression of type II
deiodinase, the enzyme involved in the conversion of T4 to T3 in central nervous system,
consequentially leading to decreased conversion of T4 to T3 (1,2,36). Propranolol has been
shown to be effective in reducing symptom severity in women with severe premenstrual
syndrome (37), and several small studies have shown that propranolol is effective in both the
treatment and prevention of PTSD (38,39). Taken together, these findings suggest that
increased T4 to T3 conversion in both periphery and brain might be pathophysiologically
relevant in MRMD.
It must be noted, however, that in the present study not all thyroid hormones were
supportive of increased T4 to T3 conversion in MRMD women since T3 concentrations
were not elevated in MRMD women as a whole. Greater T4 to T3 conversion together with
elevated T3 concentrations have been previously reported in men with combat related PTSD
(5–8) and in women with PTSD due to childhood SA (10). It is important to emphasize that
our participants did not have current PTSD. In the absence of PTSD, it is possible that in
women with MRMD, certain compensatory mechanisms might be responsible for keeping
T3, which is the most potent thyroid hormone, within the normal range. For example, lower
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free T4, which we documented in MRMD, would be expected, via feedback regulation at the
pituitary, to increase TSH that would consequently lead to an augmented T4 production by
the thyroid gland. However, TSH levels were not significantly elevated in response to lower
free T4 concentrations in MRMD women as a whole when compared to non-MRMD
women, suggesting possible alterations in the normal feedback regulation of the HPT-axis
that may represent a protective mechanism preventing overt stimulation with T3.
In addition to the HPT-axis profile in all MRMD women noted above, we extended our
previous results (22) and partially supported our a priori hypotheses by showing that a
history of SA identifies a unique subgroup of MRMD women with elevated T3
concentrations when compared to non-MRMD women with a SA history. This is consistent
with other prior work as well, demonstrating a different impact of an abuse history on
cardiovascular and neuroendocrine reactivity to mental stress and beta-adrenergic receptor
responsivity in women with MRMD versus women without MRMD (13,26,40). There are a
number of sociodemographic factors, such as time elapsed after last traumatic experience
and/or age at the time of first trauma that might influence HPT-axis measures and the
relationship of thyroid hormone concentrations to symptoms, and could account for the
differential effect of SA on T3 concentrations in the two diagnostic groups (41,42). In our
study, however, the MRMD and non-MRMD women were similar in age at first SA
experience and time elapsed after last SA episode suggesting that these factors are unlikely
to contribute to the SA-related differences in T3 concentrations in the two diagnostic groups.
Another possibility for the diagnosis related differences in the association that SA had on T3
concentrations may relate to coping mechanisms. It has been suggested that different
adaptive responses to traumatic stress may influence whether the HPT-axis is activated or
suppressed (3,6). For example, in combat situations involving “fight or flight”, mobilization
of the HPT-axis is necessary for survival whereas in war prisoners, serious threat is
associated with powerlessness and therefore a “shutting down” or immobilization of the
HPT-axis might be a more adaptive strategy for survival (3,6). Although in the current study
coping strategies were not evaluated, we can speculate that the non-MRMD women might
employ avoidant coping strategies following SA, as a recent review indicates (43), and
hence an ‘immobilization’ response leading to lower T3 concentrations. In contrast, the
elevated total T3 seen in the women with MRMD and a SA history may be part of an
arousal response because, in addition to the evidence for increased conversion of T4 to T3
that we found in all MRMD women, the thyroid gland itself can, under emergency
situations, meet the body’s metabolic needs by direct secretion of T3 (44). Although
normally, the dynamics of the HPT axis are such that negative feedback mechanisms would
restore values to baseline levels, the possibility exists that increased free and total T3
concentrations could be sustained in the face of severe stress (45). At the same time, because
T3 can easily enter the brain and promote noradrenergic neurotransmission (46), increased
T3 may perpetuate further arousal. This is consistent with our prior work showing that
MRMD women with an abuse history have greater norepinephrine reactivity to stress
relative to non-abused MRMD women, while an abuse history was not associated with
differences in norepinephrine reactivity in non-MRMD women (13). Thus, the persistent
elevation of total T3 seen in the women with MRMD and a history of SA (and also in men
with combat-related PTSD) may represent an adaptation gone awry if the thyroid system
continues to prepare the organism for a severe stressor that no longer exists but somehow
remains encoded in the brain (45).
Finally, a SA history was associated with an increased TSH concentration, irrespective of
MRMD status, suggesting increased central HPT-axis drive associated with SA. Thus, our
hypothesis that only MRMD women would show an effect of SA on HPT-axis measures
was not supported. We also observed a trend for increased free T3 binding in women with
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SA histories possibly suggesting a compensatory mechanism from overt stimulation that
increased central drive of HPT-axis might cause. Findings of elevated TSH concentrations in
women with a SA history may help to explain the previous consistent findings for greater
variability in TSH concentrations in MRMD women when compared to non-MRMD women
(19–21). Since it is well established that SA histories are more prevalent among MRMD
women when compared to non-MRMD women (12,13), greater TSH variability in MRMD
women reported previously might be explained by a higher proportion of women with a SA
history in the MRMD group. Our findings for elevated TSH associated with a SA history is
consistent with both our previous study showing that MRMD women with a SA history
exhibited 75% higher TSH concentrations when compared with non-abused MRMD women
and with non-abused non-MRMD women (22), and is also consistent with a study in combat
veterans with PTSD (6).
The major limitation of our study is that HPT-axis hormones were evaluated at a single time
point. A single assessment of the HPT-axis measures might not give a valid picture of the
dynamic function of the axis. Thus, in general, for all dynamic endocrine testing
pharmacologic challenge and/or repeated measured are preferred. Lack of control for
menstrual cycle phase might also be considered another limitation. We and others have
previously shown that concentrations of HPT-axis hormones are different in the luteal
versus follicular phases of the menstrual cycle (13,19). However, MRMD and SA-related
differences in HPT-axis hormone concentrations remained consistent in both cycle phases
(13, 19). On the other hand, the major strengths of this study included prospective
assessment for MRMD and the use of well-validated instruments for assessment of
psychiatric disorders and abuse histories.
In conclusion, our results suggest that both MRMD and SA histories may be associated with
unique HPT-axis disturbances, while also suggesting that a MRMD moderates the influence
of SA on free and total T3 concentrations, the most biologically active thyroid hormone.
Moreover, our results indicate that the unique HPT-axis abnormalities seen in the MRMD
sample (increased T4 to T3 conversion coupled with low free T4) is related to more severe
premenstrual symptomatology, underscoring the pathophysiological relevance of this profile
in MRMD. Finally, SA histories may be associated with increased central drive of the HPT-
axis as suggested by elevated TSH concentrations. Since polymorphisms in the transporter
genes that actively transport thyroid hormones through the blood-brain barrier are related to
different mental-health sequalea (1,2), future studies exploring the association of such
genetic polymorphisms with MRMD symptoms, and the moderating influence of an abuse
history on that association, may be indicated. One remarkable feature of these findings is
that, on average, it had been nearly twenty years since women had experienced sexual abuse,
suggesting long-term, persistent disturbance in HPT-axis function following severe
traumatic stress, as others have shown following combat exposure (5–8). Lifetime
prevalence of SA is approximately 22% in the general female population (9) and is
associated with increased risk for psychiatric and somatic disorders (23,47,48). Our findings
add to existing evidence and suggest that dysregulation of endocrine function can persists
for years after traumatic experiences and may be an important underlying mechanism
contributing to increased risk for poor health in SA victims. Healthcare providers should
maintain a high level of suspicion for subclinical thyroid dysfunction and consider screening
for HPT-axis dysfunction in women with a MRMD diagnosis and/or a SA history.
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DRSP Daily record of severity of problems
DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders 4th edition-Text
revision
HPT hypothalamus-pituitary-thyroid
MRMD menstrually related mood disorder




TBG thyroid binding globulin
TRH thyrotropin-releasing hormone
TSH thyroid stimulating hormone
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Concentrations of thyroid stimulating hormone (± SEM) stratified by MRMD status and SA
histories.
Abbreviations: MRMD = menstrually related mood disorders; SA = sexual abuse; SEM =
standard error of mean.
SA histories > no SA histories: F (3, 108) = 4.88, p=0.03.
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Total T3/free T4 ratio (± SEM) stratified by MRMD status and SA histories.
Abbreviations: MRMD = menstrually related mood disorders; T4 = thyroxin; T3 = tri-
iodothyronine; SA = sexual abuse; SEM = standard error of mean.
MRMD > non-MRMD: F (3, 108) = 7.82, p=0.01.
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Table 1
Demographic characteristics and psychiatric histories of all women (n=109) stratified by MRMD status and
SA history; mean ± SD, n (%).
MRMD, n=57 Non-MRMD, n=52
SA, n=23 No SA, n=34 SA, n=18 No SA, n=34
Age, years 32.43 ± 6.27 35.94 ± 8.37 35.78 ± 7.13 33.47 ± 7.97
Race, white, n(%) 15 (65) 24 (71) 12 (67) 21 (62)
Age at first SA, years 10.17 ± 5.69 - 13.00 ± 7.27 -
Time after last SA, years 19.52 ± 8.10 - 18.61 ± 8.89 -
Depression history, n(%) A 11 (48) 11 (32) 12 (67) 5 (15)
Anxiety history, n(%) 3 (13) 9 (27) 4 (22) 2 (6)
PTSD history, n(%) A 2 (9) 2 (6) 9 (50) 0
Alcohol and/or substance abuse and/or dependence history, n(%) A,B 11 (48) 2 (6) 6 (33) 1 (3)
MRMD - menstrually related mood disorders; SA – sexual abuse; PTSD – post-traumatic stress disorder.
A
non-MRMD women: SA > no SA, p < .05
B
MRMD women: SA > no SA, P < .05
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Table 2
Mean concentration of HPT-axis measures in four subgroups of women; mean ± SD.
MRMD, n=57 Non-MRMD, n=52
SA, n=23 No SA, n=34 SA, n=18 No SA, n=34
TSH, μU/mL A 1.71±0.85 1.45±0.66 2.10 ±1.15 1.63±0.74
Free T4, ng/dL B 0.92±0.18 0.90±0.19 0.99±0.23 1.06±0.20
Total T4, μg/dL B 7.13±1.08 6.91±1.11 7.73±1.37 7.49±1.21
Free T3, ng/dL C 2.43±0.68 2.31±0.45 2.04±0.50 2.41±0.50
Total T3, ng/dL C 141.85±29.57 132.35±17.54 131.01±21.07 138.64±21.19
TBG μg/mL 19.82±3.88 18.79±2.82 21.08±4.37 20.14±3.68
Free T3 to free T4 ratio D 2.70±0.75 2.61±0.44 2.09±0.47 2.31±0.44
Total T3 to free T4 ratio D 158.88±42.41 151.17±31.43 136.99±32.28 135.43±30.48
Free T3 to total T3 ratio E 0.017±0.003 0.018±0.003 0.016±0.003 0.017±0.003
Free T4 to total T4 ratio 0.129±0.02 0.132±0.027 0.132±0.037 0.144±0.034
TSH = thyroid stimulating hormone; T4 = thyroxin; T3 = tri-iodothyronine; TBG = thyroid binding globulin; MRMD = menstrually related mood
disorders; SA = sexual abuse.
A
SA > no SA, p < .05
B
MRMD < non-MRMD, p <.05
C
MRMD x SA histories interaction, p < .05
D
MRMD > non-MRMD, p < .05
E
SA < no SA, p < .05
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Table 3
The association between premenstrual symptoms and thyroid hormones in all women; Spearman’s rho (p).
Premenstrual symptoms: Free T4, ng/dL Total T4, μg/dL Free T3 to free T4 ratio Total T3 to free T4 ratio
Depression −0.18 (0.07) −0.067 (0.49) 0.410 (<0.001) 0.12 (0.23)
Anxiety −0.20 (0.04) −0.191 (0.05) 0.409 (<0.001) 0.27 (0.01)
Mood lability −0.25 (0.01) −0.196 (0.04) 0.354 (<0.001) 0.24 (0.01)
Anger −0.22 (0.02) −0.206 (0.03) 0.292 (0.002) 0.26 (0.01)
Total symptom severity −0.24 (0.01) −0.21 (0.03) 0.37 (<0.001) 0.25 (0.01)
T4 = thyroxin; T3 = tri-iodothyronine.
In bold p≤0.05
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